Opioid Dependence and Non-Canonical Targets for Medication Development
Sunday April 03, 2022
Eastern Time (ET)
University of Kentucky College of Pharmacy
Opioid use disorder (OUD) is a leading cause of morbidity and mortality in the United States. Yet, very few therapeutic options are available to individuals suffering from opioid use disorder, indicating novel drug development for OUD is critically needed. This panel, chaired by Dr. Jill Turner, the 2021 Division for Neuropharmacology Early Career Awardee, will discuss new and exciting directions in medication development for this debilitating disorder, centered on modulating neuroinflammatory responses to opioid exposure and withdrawal.
- Virginia Tech
Peripheral-Central Immune Crosstalk and Affective Dysruption Salient to OUD
Dr. Georgia Hodes (Virginia Tech) will detail her work linking peripheral and central cytokine signaling in driving affective symptomology associated with opioid use disorder.
Lilian Goncalves Custodio
- University of Kentucky
Cell-type Specific Transcriptome and Genome Alterations in OUD
Dr. Lilian Goncalves Custodio (Univ Kentucky) will discuss her work examining the cell-type specific genomic alterations underlying individual vulnerability to escalation of opioid intake and present data from the human population linking these mechanisms to real-life risk potential.
- Tufts University, SBIR collaboration
New Approaches to Therapeutic Delivery for OUD
Dr. Fair Vassoler (Tufts Univ) will discuss her recent collaborative work examining the use of nanoparticles in facilitating discrete delivery of therapeutics across the BBB for controlled release to specific cell types for use in OUD.
Talks will be selected from submitted abstracts.